Cargando…

Successful treatment of anogenital warts with single dose Bacillus Calmette Guerin vaccine without prior sensitization in tuberculosis endemic country: Two case report

Anogenital Warts (AGWs) are benign proliferations caused by Human Papillomavirus (HPV) infection on the genital or anal areas. Various therapeutic options are available for the treatment of AGWs but there is no best or ideal therapy, and the recurrence of AGWs is significantly high. A promising new...

Descripción completa

Detalles Bibliográficos
Autores principales: Achdiat, Pati Aji, Suwarsa, Oki, Hidayat, Yudi Mulyana, Shafiee, Mohamad Nasir, Dwiyana, Reiva Farah, Gunawan, Hendra, Rowawi, Rasmia, Johan, Reyshiani
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2023
Materias:
HPV
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10072059/
https://www.ncbi.nlm.nih.gov/pubmed/36942667
http://dx.doi.org/10.1080/21645515.2023.2187591
_version_ 1785019310860664832
author Achdiat, Pati Aji
Suwarsa, Oki
Hidayat, Yudi Mulyana
Shafiee, Mohamad Nasir
Dwiyana, Reiva Farah
Gunawan, Hendra
Rowawi, Rasmia
Johan, Reyshiani
author_facet Achdiat, Pati Aji
Suwarsa, Oki
Hidayat, Yudi Mulyana
Shafiee, Mohamad Nasir
Dwiyana, Reiva Farah
Gunawan, Hendra
Rowawi, Rasmia
Johan, Reyshiani
author_sort Achdiat, Pati Aji
collection PubMed
description Anogenital Warts (AGWs) are benign proliferations caused by Human Papillomavirus (HPV) infection on the genital or anal areas. Various therapeutic options are available for the treatment of AGWs but there is no best or ideal therapy, and the recurrence of AGWs is significantly high. A promising new therapy that is currently being evaluated is immunotherapy with the intralesional Bacillus Calmette-Guérin (BCG) vaccine. Two cases of a 23-year-old woman and a 41-year-old man were presented with manifestations of condyloma acuminata type AGWs. The patients were immunocompetent and received single dose intralesional BCG vaccine on the largest lesion. Clinical improvements of AGWs lesions were noted starting on the 14th day after receiving therapy by the disappearance of some lesions with no recurrence and side effects. Intralesional BCG vaccine activates the immune system, treats other AGWs lesions that do not receive an intralesional injection, and also prevents recurrence. Although the intralesional BCG vaccine is effective for treating AGWs, further evaluation is still needed for its recurrence.
format Online
Article
Text
id pubmed-10072059
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Taylor & Francis
record_format MEDLINE/PubMed
spelling pubmed-100720592023-04-05 Successful treatment of anogenital warts with single dose Bacillus Calmette Guerin vaccine without prior sensitization in tuberculosis endemic country: Two case report Achdiat, Pati Aji Suwarsa, Oki Hidayat, Yudi Mulyana Shafiee, Mohamad Nasir Dwiyana, Reiva Farah Gunawan, Hendra Rowawi, Rasmia Johan, Reyshiani Hum Vaccin Immunother HPV Anogenital Warts (AGWs) are benign proliferations caused by Human Papillomavirus (HPV) infection on the genital or anal areas. Various therapeutic options are available for the treatment of AGWs but there is no best or ideal therapy, and the recurrence of AGWs is significantly high. A promising new therapy that is currently being evaluated is immunotherapy with the intralesional Bacillus Calmette-Guérin (BCG) vaccine. Two cases of a 23-year-old woman and a 41-year-old man were presented with manifestations of condyloma acuminata type AGWs. The patients were immunocompetent and received single dose intralesional BCG vaccine on the largest lesion. Clinical improvements of AGWs lesions were noted starting on the 14th day after receiving therapy by the disappearance of some lesions with no recurrence and side effects. Intralesional BCG vaccine activates the immune system, treats other AGWs lesions that do not receive an intralesional injection, and also prevents recurrence. Although the intralesional BCG vaccine is effective for treating AGWs, further evaluation is still needed for its recurrence. Taylor & Francis 2023-03-21 /pmc/articles/PMC10072059/ /pubmed/36942667 http://dx.doi.org/10.1080/21645515.2023.2187591 Text en © 2023 The Author(s). Published with license by Taylor & Francis Group, LLC. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License (http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) ), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited, and is not altered, transformed, or built upon in any way. The terms on which this article has been published allow the posting of the Accepted Manuscript in a repository by the author(s) or with their consent.
spellingShingle HPV
Achdiat, Pati Aji
Suwarsa, Oki
Hidayat, Yudi Mulyana
Shafiee, Mohamad Nasir
Dwiyana, Reiva Farah
Gunawan, Hendra
Rowawi, Rasmia
Johan, Reyshiani
Successful treatment of anogenital warts with single dose Bacillus Calmette Guerin vaccine without prior sensitization in tuberculosis endemic country: Two case report
title Successful treatment of anogenital warts with single dose Bacillus Calmette Guerin vaccine without prior sensitization in tuberculosis endemic country: Two case report
title_full Successful treatment of anogenital warts with single dose Bacillus Calmette Guerin vaccine without prior sensitization in tuberculosis endemic country: Two case report
title_fullStr Successful treatment of anogenital warts with single dose Bacillus Calmette Guerin vaccine without prior sensitization in tuberculosis endemic country: Two case report
title_full_unstemmed Successful treatment of anogenital warts with single dose Bacillus Calmette Guerin vaccine without prior sensitization in tuberculosis endemic country: Two case report
title_short Successful treatment of anogenital warts with single dose Bacillus Calmette Guerin vaccine without prior sensitization in tuberculosis endemic country: Two case report
title_sort successful treatment of anogenital warts with single dose bacillus calmette guerin vaccine without prior sensitization in tuberculosis endemic country: two case report
topic HPV
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10072059/
https://www.ncbi.nlm.nih.gov/pubmed/36942667
http://dx.doi.org/10.1080/21645515.2023.2187591
work_keys_str_mv AT achdiatpatiaji successfultreatmentofanogenitalwartswithsingledosebacilluscalmetteguerinvaccinewithoutpriorsensitizationintuberculosisendemiccountrytwocasereport
AT suwarsaoki successfultreatmentofanogenitalwartswithsingledosebacilluscalmetteguerinvaccinewithoutpriorsensitizationintuberculosisendemiccountrytwocasereport
AT hidayatyudimulyana successfultreatmentofanogenitalwartswithsingledosebacilluscalmetteguerinvaccinewithoutpriorsensitizationintuberculosisendemiccountrytwocasereport
AT shafieemohamadnasir successfultreatmentofanogenitalwartswithsingledosebacilluscalmetteguerinvaccinewithoutpriorsensitizationintuberculosisendemiccountrytwocasereport
AT dwiyanareivafarah successfultreatmentofanogenitalwartswithsingledosebacilluscalmetteguerinvaccinewithoutpriorsensitizationintuberculosisendemiccountrytwocasereport
AT gunawanhendra successfultreatmentofanogenitalwartswithsingledosebacilluscalmetteguerinvaccinewithoutpriorsensitizationintuberculosisendemiccountrytwocasereport
AT rowawirasmia successfultreatmentofanogenitalwartswithsingledosebacilluscalmetteguerinvaccinewithoutpriorsensitizationintuberculosisendemiccountrytwocasereport
AT johanreyshiani successfultreatmentofanogenitalwartswithsingledosebacilluscalmetteguerinvaccinewithoutpriorsensitizationintuberculosisendemiccountrytwocasereport